Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes

Area of Science:

• Neuroscience
• Pharmacology
• Cell Biology

Background:

• Amyotrophic lateral sclerosis (ALS) treatment options are limited, with riluzole being the primary drug.
• Riluzole's mechanism of action is not fully understood, with proposed roles in glutamate release inhibition and antioxidant activity.
• Investigating riluzole's direct antioxidant effects is crucial for understanding its therapeutic potential in ALS.

Purpose of the Study:

• To selectively assess the direct antioxidant effect of riluzole using human neuroblastoma cell lines.
• To investigate the efficacy of riluzole in counteracting oxidative and nitrosative stress in cellular models of ALS.

Main Methods:

• Utilized human SH-SY5Y neuroblastoma cell lines, including parental and G93A SOD1 mutant variants.
• Exposed cells to hydrogen peroxide (H₂O₂) for oxidative stress and 3-morpholino-sydnonimine (SIN-1) for reactive nitrogen species (RNS) induction.
• Quantified cell death and reactive oxygen species (ROS) levels to evaluate riluzole's protective effects.

Main Results:

• Riluzole (1–10 µM) effectively reduced cell death and ROS increase induced by H₂O₂ exposure in parental SH-SY5Y cells.
• Riluzole showed no efficacy in SH-SY5Y cells overexpressing the G93A SOD1 mutation, which have elevated ROS levels.
• Riluzole failed to prevent cell death induced by the RNS donor SIN-1.

Conclusions:

• The findings support a direct antioxidant action of riluzole.
• The lack of efficacy in the SOD1 model suggests differing pathogenic mechanisms in ALS subtypes.
• Riluzole's ineffectiveness against nitrosative stress highlights the potential benefit of combination therapies, such as with edaravone, for ALS patients.